Living Cell Technologies (ASX:LCT) - Executive Chairman, Professor Bernie Tuch
Executive Chairman, Professor Bernie Tuch
Source: Living Cell Technologies
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Biotech company Living Cell Technologies (LCT) raises $1.285 million through a private placement to boost its research into Parkinson’s Disease
  • The company issued 257 million new fully-paid ordinary shares to professional and sophisticated investors of advisory firm Alignment Capital at 0.5 cents
  • LCT will use the money to support its research to fight Parkinson’s disease, with its NTCELL product advancing to a third clinical trial
  • Company Executive Chairman Professor Bernie Tuch says the money will provide essential funds and support from biotech investors
  • Shares in LCT are up 20 per cent and are trading at 0.6 cents at 2:29 pm AEST

Biotech company Living Cell Technologies (LCT) has raised $1.285 million through a private placement to boost its research into Parkinson’s Disease.

The company issued 257 million new fully-paid ordinary shares to professional and sophisticated investors of advisory firm Alignment Capital at 0.5 cents.

LCT said it would use the money to support its research to fight Parkinson’s disease, with its NTCELL product advancing to a third clinical trial.

The aim of this trial is to determine whether NTCELL provides neuroprotection to pause or delay the natural progression of Parkinson’s.

Living Cell Executive Chairman Professor Bernie Tuch said the placement would provide essential funds and support from biotech investors.

“We are delighted to commence a relationship with Alignment Capital and look forward to its future development,” Professor Tuch stated.

“Alignment Capital has a track record of successful biotech investments and their support will be highly beneficial as we progress towards human trials of NTCELL.”

The placement follows LCT’s move to apply artificial intelligence to its third clinical trial of NTCELL in Parkinson’s under an agreement with OptiCellAI.

LCT in March signed a research agreement with the University of Technology Sydney to allow for the production of NTCELL in Australia.

Shares in Living Cell Technologies were up 20 per cent and were trading at 0.6 cents at 2:29 pm AEST.

LCT by the numbers
More From The Market Herald

" Dimerix’s (ASX:DXB) DMX-700 study shows significant 80pc reduction in lung injury

Dimerix (ASX:DXB) has released its pipeline program DMX-700 study results which indicated a significant 80 per…

" Tesoro Gold (ASX:TSO) confirms El Zorro as a new Chilean Gold District

Tesoro Gold (ASX:TSO) has confirmed its El Zorro project as a new Chilean Intrusive Related Gold…
OncoSil Medical (ASX:OSL) - Managing Director & CEO, Nigel Lange

" Bupa UK becomes first insurance company to reimburse for OncoSil Medical’s (ASX:OSL) namesake device

Bupa UK Insurance has become the first health insurance company to provide reimbursement for OncoSil Medical's…

" Patrys (ASX:PAB) completes second engineering run for PAT-DX1

Biotech junior Patrys (ASX:PAB) has completed a second engineering run for its PAT-DX1 cancer antibody candidate…